Myeloproliferative Disorders: Can Prognosis Be Predicted?

Published on

Topics include: Understanding

Dr. Ruben Mesa describes various tools used to better predict disease behavior, specifically symptoms, among polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis. Mesa lays out the overall survival rates based on data collected and what we’ve learned. Dr. Jorge Cortes discusses the scores or “median survival” and how they are used to calculate statistics for survival. Both help us understand the efficacy and limitations of these tools.

View more programs featuring and

Produced in association with

Related Programs

Living Stronger and Longer with MPNs

Mayo Clinic expert Dr. Ruben Mesa shares his thoughts on how treatment and research can be further improved for patients living with MPNs.


Should Patients With a Less Advanced MPN Take a JAK2 Inhibitor?

How early should a JAK2 inhibitor be prescribed for myelofibrosis or other myeloproliferative conditions? Approved and investigational JAK2 inhibitors are now being used by patients with more advanced and aggressive MPNs, but not as often in earlier stages. Watch now as Dr. Srdan Verstovsek gives his opinion on how JAK inhibitors should be used.


Understanding Disease Burden Among MPNs

Is it possible to pinpoint the source of symptoms in MPNs? Not always, according to Drs. Ruben Mesa and Jorge Cortes. Both experts focus on understanding disease burden among MPNs.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on October 26, 2015